A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BTP / breakthrough pain

[Related PubMed/MEDLINE]
Total Number of Papers: 127
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BTP  (>> Co-occurring Abbreviation)
Long Form:   breakthrough pain
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Oral prolonged-release Oxycodone-Naloxone: analgesic response, safety profile, and factors influencing the response in advanced cancer patients. OXN
2019 Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain. ESAS, IR, OR
2019 The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study. BPI, NSAIDs, VAS
2018 Documentation of breakthrough pain in narrative clinical records of children with life-limiting conditions: Feasibility of a retrospective review. LTIs
2018 Evaluation of Quality of Life and Satisfaction of Patients with Neuropathic Pain and Breakthrough Pain: Economic Impact Based on Quality of Life. CNP, ESAS
2018 Evaluation of the quality of care of elderly patients with chronic and breakthrough pain treated with opioids: SAND study. CP, VAS
2018 Initial titration with 200 mug fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. AEs, FBTs
2018 Nonresponsiveness and Susceptibility of Opioid Side Effects Related to Cancer Patients' Clinical Characteristics: A Post-Hoc Analysis. ADRs, NRs
2018 Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study. ESAS, LGM
10  2018 Pain Intensity Factors Changing Breakthrough Pain Prevalence in Patients with Advanced Cancer: A Secondary Analysis of a Cross-Sectional Observational International Study. PI
11  2018 Prevalence and Characterization of Breakthrough Pain Associated with Chronic Low Back Pain in the South of Spain: A Cross-Sectional, Multicenter, Observational Study. CLBP
12  2018 Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study. AEs, FBSF
13  2018 The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients. EOL, MESOR
14  2017 Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study. AEs, PI, SF-12v2, SFTs
15  2017 Combined application of diclofenac and celecoxib with an opioid yields superior efficacy in metastatic bone cancer pain: a randomized controlled trial. NSAIDs, RR, VAS
16  2017 Development and performance of a diagnostic/prognostic scoring system for breakthrough pain. NBC, PGS
17  2017 Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study. BPI
18  2017 Mediation of Movement-Induced Breakthrough Cancer Pain by IB4-Binding Nociceptors in Rats. CPA, IB4
19  2017 PainVision Apparatus for Assessment of Efficacy of Pulsed Radiofrequency Combined with Pharmacological Therapy in the Treatment of Postherpetic Neuralgia and Correlations with Measurements. NRSSIS, PD, PHN, PP, PRF, SF-Mcgill, VAS
20  2017 Procedural Pain in Palliative Care: Is It Breakthrough Pain? A Multicenter National Prospective Study to Assess Prevalence, Intensity, and Treatment of Procedure-related Pain in Patients With Advanced Disease. ---
21  2017 The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids. SLF
22  2017 Ultrasound-Guided Radiofrequency Treatment of Intercostal Nerves for the Prevention of Incidental Pain Arising Due to Rib Metastasis. RF
23  2017 [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl]. OTFC, ROOs
24  2016 Development, validation and psychometric properties of a diagnostic/prognostic tool for breakthrough pain in mixed chronic-pain patients. BPI, CP, PCA
25  2016 Fentanyl in a pectin gel treating breakthrough pain in vertebral compression fracture due to multiple myeloma: A descriptive study of three cases. ---
26  2016 Is it possible to detect an improvement in cancer pain management? A comparison of two Norwegian cross-sectional studies conducted 5years apart. CP
27  2016 Nurse-based monitoring and management of breakthrough pain in an acute pain relief and palliative care unit. ---
28  2015 Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain. ABPAT
29  2015 Breakthrough pain management in patients undergoing radiotherapy: a national survey on behalf of the Palliative and Supportive Care Study Group. AIRO
30  2015 Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. AE, BPI, CI, LDQ, QOL, SLF, VAS
31  2015 Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain. INFS
32  2015 Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain. FBT
33  2015 Italian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settings. IOPS, ONC, PCU
34  2015 National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes. GAD-7, PHQ-2, SF-12
35  2015 Pain characteristics and analgesic treatment in an aged adult population: a 4-week retrospective analysis of advanced cancer patients followed at home. ---
36  2015 Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction. ITT, PCIA
37  2015 Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes. AEs, HADS, PI, QOL, SF-12v2, SFT
38  2015 [Treatment of breakthrough pain in cancer patients]. ---
39  2014 A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. ---
40  2014 A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients. ATC, FBTs
41  2014 A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer. FE, SE, SPID
42  2014 A review of rapid-onset opioids for breakthrough pain in patients with cancer. ROOs, TIRF
43  2014 Assessing age and gender in studies of breakthrough pain medications. ---
44  2014 Breakthrough pain in elderly patients with cancer: treatment options. ---
45  2014 Breakthrough pain in patients with controlled or uncontrolled basal pain: an observational study. ---
46  2014 Effectiveness of opioid rotation in the control of cancer pain: the ROTODOL study. AEs, AP, NRS, OR
47  2014 End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids? ATC, ER
48  2014 Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. CRT, FPNS, HNC
49  2014 Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article. tmax
50  2014 The use of Instanyl in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study. ADRs, BPI-SF, PTSS
51  2014 Utilization of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study. GPs
52  2013 Administration of four different doses of gabapentin reduces awakening from breakthrough pain and adverse effects in outpatients with neuropathic pain during the initial titration. ---
53  2013 An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects. CL, INFS, PK, PopPK
54  2013 Beyond the traditional definition of breakthrough pain: an observational study. ---
55  2013 Breathlessness with pulmonary metastases: a multimodal approach. PCA
56  2013 Cancer pain management in an oncological ward in a comprehensive cancer center with an established palliative care unit. PCU, PMI
57  2013 Considerations in selecting rapid-onset opioids for the management of breakthrough pain. ---
58  2013 Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study. AEs, BTcP, BTncP, sublingual fentanyl ODT, VAS
59  2013 Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. PI
60  2013 Grading clinical guidelines for the use of transmucosal immediate-release fentanyl products in breakthrough pain. QOL, TIRF
61  2013 Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study. IRMS, VAS
62  2013 The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. SLF
63  2012 A comprehensive review of rapid-onset opioids for breakthrough pain. ---
64  2012 A review of the pharmacokinetic profile of transmucosal fentanyl formulations. ---
65  2012 Breakthrough pain in patients referred to pain clinics: the Italian pain network retrospective study. ---
66  2012 Breakthrough pain-novel analgesics. ---
67  2012 Breakthrough pain: the importance of baseline analgesic regimen with opioids. ---
68  2012 Clinical effectiveness and safety of OROS hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients. ---
69  2012 Pharmacotherapy for breakthrough cancer pain. ---
70  2012 Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. INFS, PK
71  2012 Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. MDS, SDS
72  2012 Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies. ---
73  2011 Acupuncture: a treatment for breakthrough pain in cancer? ---
74  2011 Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. FBT, PASS
75  2011 Fentanyl buccal tablets for the treatment of breakthrough pain. FBT
76  2011 Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. AE, FBT
77  2011 Movement-evoked breakthrough cancer pain despite intrathecal analgesia: a prospective series. ITA, MEPI, NRS, SRPI
78  2011 Opioid delivery in the treatment of cancer breakthrough pain: a review of routes of administration. ---
79  2011 Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. EPOS, KPS, MMSE
80  2011 The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. CI, FBT, SPID
81  2010 A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. FBT, PID, PR
82  2010 Assessment and classification of cancer breakthrough pain: a systematic literature review. ---
83  2010 Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. ---
84  2010 Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. BBHI 2, BPI-SF
85  2010 Breakthrough pain: progress in management. ---
86  2010 Cancer pain: an age-based analysis. HRQoL
87  2010 Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. ADPREM, CRM
88  2010 Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy. FBT
89  2010 Idiopathic breakthrough pain: a new hypothesis. ---
90  2010 Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. AEs, ATC, FBT
91  2010 Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. INFS
92  2010 Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: a cross-sectional study. BPQ
93  2010 Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. PID, SLF
94  2010 Time to pain relief after immediate-release morphine in episodic pain: the TIME study. IR, NRS
95  2010 Treatment of severe cancer pain by transdermal fentanyl. ---
96  2009 A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. INFS, OTFC, PI, PID
97  2009 Cancer and breakthrough pain's impact on a diverse population. HRQoL
98  2009 Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. AEs, FBT
99  2009 Standard therapy with opioids in chronic pain management : ORTIBER study. IR, ORTIBER, SR, VAS
100  2009 Treatment strategies for cancer patients with breakthrough pain. ---